Adaptive Biotechnologies (ADPT) Competitors $6.39 +0.39 (+6.50%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ADPT vs. CRSP, DNLI, TWST, VCEL, SWTX, KYMR, IOVA, BEAM, RXRX, and IBRXShould you be buying Adaptive Biotechnologies stock or one of its competitors? The main competitors of Adaptive Biotechnologies include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Vericel (VCEL), SpringWorks Therapeutics (SWTX), Kymera Therapeutics (KYMR), Iovance Biotherapeutics (IOVA), Beam Therapeutics (BEAM), Recursion Pharmaceuticals (RXRX), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry. Adaptive Biotechnologies vs. CRISPR Therapeutics Denali Therapeutics Twist Bioscience Vericel SpringWorks Therapeutics Kymera Therapeutics Iovance Biotherapeutics Beam Therapeutics Recursion Pharmaceuticals ImmunityBio Adaptive Biotechnologies (NASDAQ:ADPT) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Do institutionals and insiders hold more shares of ADPT or CRSP? 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 6.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable valuation & earnings, ADPT or CRSP? CRISPR Therapeutics has higher revenue and earnings than Adaptive Biotechnologies. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$177.28M5.32-$225.25M-$1.34-4.77CRISPR Therapeutics$200M17.38-$153.61M-$2.83-14.39 Is ADPT or CRSP more profitable? Adaptive Biotechnologies has a net margin of -110.13% compared to CRISPR Therapeutics' net margin of -118.13%. CRISPR Therapeutics' return on equity of -12.15% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-110.13% -62.06% -26.82% CRISPR Therapeutics -118.13%-12.15%-10.35% Do analysts recommend ADPT or CRSP? Adaptive Biotechnologies currently has a consensus target price of $6.75, suggesting a potential upside of 5.63%. CRISPR Therapeutics has a consensus target price of $77.93, suggesting a potential upside of 91.39%. Given CRISPR Therapeutics' higher probable upside, analysts clearly believe CRISPR Therapeutics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75CRISPR Therapeutics 1 Sell rating(s) 8 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.44 Does the MarketBeat Community prefer ADPT or CRSP? CRISPR Therapeutics received 375 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. Likewise, 64.83% of users gave CRISPR Therapeutics an outperform vote while only 57.58% of users gave Adaptive Biotechnologies an outperform vote. CompanyUnderperformOutperformAdaptive BiotechnologiesOutperform Votes9557.58% Underperform Votes7042.42% CRISPR TherapeuticsOutperform Votes47064.83% Underperform Votes25535.17% Which has more risk and volatility, ADPT or CRSP? Adaptive Biotechnologies has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Does the media favor ADPT or CRSP? In the previous week, Adaptive Biotechnologies and Adaptive Biotechnologies both had 7 articles in the media. Adaptive Biotechnologies' average media sentiment score of 0.92 beat CRISPR Therapeutics' score of 0.41 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryCRISPR Therapeutics beats Adaptive Biotechnologies on 10 of the 17 factors compared between the two stocks. Ad DTICackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADPT vs. The Competition Export to ExcelMetricAdaptive BiotechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$943.03M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-4.7746.7391.3417.19Price / Sales5.32411.851,116.63116.80Price / CashN/A182.1042.5837.86Price / Book3.003.894.794.78Net Income-$225.25M-$42.21M$120.07M$225.60M7 Day Performance1.43%-2.14%-1.90%-1.24%1 Month Performance45.25%4.21%11.43%3.06%1 Year Performance27.04%18.40%30.59%16.50% Adaptive Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADPTAdaptive Biotechnologies2.9488 of 5 stars$6.39+6.5%$6.75+5.6%+34.8%$943.03M$177.28M-4.77709Analyst ForecastNews CoverageGap DownCRSPCRISPR Therapeutics2.5041 of 5 stars$44.71+2.1%$77.93+74.3%-33.0%$3.82B$371.21M-15.47473Analyst ForecastDNLIDenali Therapeutics4.4235 of 5 stars$23.81+3.7%$40.40+69.7%+1.3%$3.43B$330.53M-8.49364Positive NewsGap UpTWSTTwist Bioscience2.5561 of 5 stars$48.86+2.9%$51.90+6.2%+36.7%$2.90B$312.97M-13.19990VCELVericel1.4381 of 5 stars$57.97+0.9%$59.71+3.0%+66.0%$2.86B$226.84M957.83300Analyst ForecastSWTXSpringWorks Therapeutics2.0114 of 5 stars$38.21-0.2%$69.50+81.9%+11.3%$2.84B$5.45M-9.87305KYMRKymera Therapeutics2.27 of 5 stars$43.73+3.8%$53.88+23.2%+66.0%$2.83B$87.56M-18.00170IOVAIovance Biotherapeutics4.0084 of 5 stars$7.92+1.1%$22.33+182.0%+2.8%$2.41B$1.19M-5.25500BEAMBeam Therapeutics3.4271 of 5 stars$28.63+2.5%$47.67+66.5%+5.0%$2.37B$349.64M-15.87461RXRXRecursion Pharmaceuticals2.4151 of 5 stars$7.50+7.9%$9.25+23.3%-36.3%$2.15B$44.58M-4.85400News CoverageIBRXImmunityBio2.1332 of 5 stars$3.04+5.9%$17.38+471.5%-42.2%$2.12B$7.33M-3.36590Analyst Forecast Related Companies and Tools Related Companies CRISPR Therapeutics Competitors Denali Therapeutics Competitors Twist Bioscience Competitors Vericel Competitors SpringWorks Therapeutics Competitors Kymera Therapeutics Competitors Iovance Biotherapeutics Competitors Beam Therapeutics Competitors Recursion Pharmaceuticals Competitors ImmunityBio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADPT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADPT Stock Alerts